APA (7th ed.) Citation

L, v. d. S., CAM, S., S, K., K, N., J, D., JA, D., . . . MD, L. (2023). Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood, 142(13), 1131. https://doi.org/10.1182/blood.2023020195

Chicago Style (17th ed.) Citation

L, van der Straten, et al. "Fixed-duration Venetoclax Plus Obinutuzumab Improves Quality of Life and Geriatric Impairments in FCR-unfit Patients with CLL." Blood 142, no. 13 (2023): 1131. https://doi.org/10.1182/blood.2023020195.

MLA (9th ed.) Citation

L, van der Straten, et al. "Fixed-duration Venetoclax Plus Obinutuzumab Improves Quality of Life and Geriatric Impairments in FCR-unfit Patients with CLL." Blood, vol. 142, no. 13, 2023, p. 1131, https://doi.org/10.1182/blood.2023020195.